Wells Fargo analyst Davis Maris upgraded Emergent BioSolutions to Outperform from Market Perform and raised his price target for the shares to $64 from $61. Emergent yesterday announced a much anticipated follow-on U.S. government contract for ACAM2000, its smallpox vaccine, Maris tells investors in a research note. Investors were worried about this delayed contract and were expecting a 10-year contract worth approximately $450M, well below the $2B value, adds the analyst. He believes the "major" contract removes a "major overhang" on shares of Emergent BioSolutions.